At the 24 month follow up in the integrated analysis of Zometa Femara Adjuvant Synergy Trials Z FAST and ZO FAST for postmenopausal women with HR positive stage I, II, or IIIA breast cancer, up front treatment with zoledronic acid resulted in a statistically significant 43 risk reduction in disease recurrence compared with delayed treatment with zoledronic acid, despite 19 of patients in the delayed treatment group initiating zoledronic acid cialis generic reviews It can prevent the cancer from coming back in the breast or elsewhere